IMRICOR FY 2025 RESULTS

HIGHLIGHTS:

Regulatory & Clinical

- **CE Mark** approvals under the EU Medical Device Regulation (MDR) received for second generation platform components, including the 2nd generation Vision-MR® Ablation Catheter, 2nd generation Advantage-MR® EP Recorder/Stimulator, and NorthStar®, the world's first and only MRI-native 3D mapping and guidance system
- Landmark **first-in-human** ischemic ventricular tachycardia (**VT**) ablation performed under real time MRI guidance at Amsterdam University Medical Centre, commencing the VISABL-VT clinical trial
- Completed human factors usability study for all of Imricor's products, involving physicians from close to **20 U.S. hospitals**
- Several 510(k) submissions made for FDA clearance
- Vision-MR Diagnostic Catheter and NorthStar subsequently **cleared by FDA** in January 2026
- Expanded VISABL-AFL trial to include a **new U.S. hospital**, the University of Virginia
- Added two additional U.S. hospitals to the trial in 2026: Virginia Commonwealth University and Oklahoma Heart Institute
- Two PMA modules submitted, module 3 submission is scheduled, fourth and final module will be submitted following completion of the VISABL-AFL trial
- World's first pre-clinical in vivo Pulsed Field Ablation (**PFA**) performed under real-time MRI guidance

Commercial

- European sales team **hiring and training completed**, supporting commercial readiness
- European customer pipeline increased from **7 to 40** by year end
- **Middle East** expansion progressed with two iCMR labs under construction in Saudi Arabia and continued physician engagement, including an accredited iCMR summit in Riyadh attended by close to 100 physicians
- Completed integration and testing of **NorthStar on Philips** MRI platform

Financial

- Revenue of US$292,000 for FY25 temporarily impacted by customers enrolling clinical trial patients
- Operating cash outflow of approximately US$19 million for the year
- Cash and marketable securities of approximately US$40.8 million at 31 December 2025

25 February 2026 – Melbourne, Australia (**24 February 2026** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**) today releases its FY25 Financial Results for the period ended 31 December 2025 and provides an update on its operational performance.

An investor webinar will be held at 8:15am AEDT on Wednesday 25th February 2026 (3:15pm CST on Tuesday 24th February 2026). Click here to register

Imricor's Chair and CEO, Steve Wedan, commented: "FY2025 was a defining year for Imricor. We moved from proving what is possible in iCMR to demonstrating real momentum across the platform. We achieved MDR approvals for key second generation components, including NorthStar, the world's only MRI native 3D mapping and guidance system, and we delivered the first-in-human ischemic VT ablation performed under real time MRI guidance to commence the VISABL-VT clinical trial. Just as importantly, we built the commercial foundations for scale, completing our European sales build out and expanding our European pipeline from 7 to 40 sites by year end. In the U.S., the market that truly delivers scale to Imricor, recent FDA clearances demonstrate our regulatory momentum, and this momentum will continue. We believe this is how a new standard of care gets built, milestone by milestone, with technology that is truly transformational."

ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

Media and Investor Relations Contacts:

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill
VP Corporate Strategy, Imricor
nick.corkill@imricor.com
+61 450 475 633

About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

Imricor's Products

Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. US FDA approval is in process, and further approvals in other geographies such as Australia are being planned.

Foreign Ownership Restrictions

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.